EPRXEUPRAXIA PHARMACEUTICALS INC.vs its industry peers
A metric-by-metric comparison of EUPRAXIA PHARMACEUTICALS INC. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPRX본 종목 | $299M#1 | — | 3.6x#3 | — | — | -51.3%#5 | — | -47.0%#4 | — | — | 55.9%#2 | — |
| EDSA | $38M#4 | — | 4.3x#4 | — | -100.0%#5 | -16.5%#4 | — | -81.6%#6 | — | — | 58.4%#1 | — |
| ELTP | — | — | — | — | 77.1%#2 | 1140.0%#2 | 33.0%#1 | 42.8%#3 | 38.9%#1 | 5#1 | — | — |
| ENLV | $166M#3 | 0.0x#1 | 0.1x#1 | — | — | 8329.2%#1 | — | 63.9%#1 | -0.6%#3 | — | -95.6%#6 | — |
| ETST | — | — | — | — | 7.8%#3 | 11.6%#3 | 2.5%#2 | 49.4%#2 | 12.9%#2 | 5#1 | — | — |
| EVO | $295M#2 | — | — | — | — | — | — | — | — | — | -53.1%#3 | — |
| GCAN | — | — | — | — | -73.7%#4 | -85.2%#7 | -1449.0%#3 | — | — | — | — | — |
| GDTC | $10M#5 | — | 2.1x#2 | 41.4x#1 | 395.9%#1 | -68.0%#6 | — | -60.8%#5 | — | — | -54.8%#4 | — |
| GELS | $6M#6 | — | — | — | — | -87.4%#8 | — | — | — | — | -62.5%#5 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice